The Unique U.S.-Russian Relationship in Biological Science and Biotechnology Recent Experience and Future Directions (2013) / Chapter Skim
Currently Skimming:
Appendix E.5: Rusnano and Other Russian Investors
Appendix E.5: Rusnano and Other Russian Investors
Pages 221-222
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 221... ...
/$500 million Maxwell Biotech/U.S.-Russia/Russian Venture Company/$100 million RVC Intrafund/Russia/Russian Venture Company/$68 million RVC Biofund/Russian Venture Company/$50 million 2: Russian Investments in Companies: Company/Location/Investor/Commitment ProBonoBil U.K./Russia/Rusnano/$300 million Nearmedic Plus/Russia/Rusnano/$41 million Magnisense/France/Rusnano/$38 million SynBio/Russia/Rusnano/$31 million Panacela Laboratories/U.S./Rusnano/$26 million 221
|
From page 222... ...
http://www.bindbio.com/content/pages/company/aboutrussia.jsp Selecta Biosciences (Watertown, Mass.) : Development in Russia of synthetic vaccine nanoparticles that encapsulate adjuvant and either a T-cell epitope or allergen in a polylactic acid-co-glycolic acid core surrounded by a lipid monolayer and a PEG shell decorated with a B-cell epitope.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.